Evidence map›Paper›PMID 24439426›Full record

ArticleTrends in immunology2014

Tumor antigenicity revealed.

Peter A Savage

Open access · greenAbstract readComment
In one paragraph

Article in Trends in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting cancer with kinase inhibitors.The Journal of clinical investigation · 2015
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Peter A SavageDepartment of Pathology, University of Chicago, Chicago, IL 60605, USA. Electronic address: psavage@bsd.uchicago.edu.
University of Chicago · US

Funding

Development and specificity of endogeneous tumor-infiltrating regulatory T cellsR01CA160371 · NCI · UNIVERSITY OF CHICAGO · PI SAVAGE, PETER AIDAN · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA160371
6 · The paper itself

Abstract

The extent to which mutated peptide antigens encoded by somatic mutations contribute to tumor antigenicity in human cancer patients has been unclear. Two recent studies using tumor exome sequencing to predict candidate mutated antigens provide insight into this question.

Indexed as

AnimalsHumansImmunotherapy, AdoptiveNeoplasmsT-Lymphocytes

Identifiers

PMID24439426
PMCPMC3932747
OpenAlexW1985681197

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.